Upcoming IPO: Biocon plans to list biosimilars business on stock exchanges by March 2026

Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new launches. The company aims to complete its integration with Viatris and refinance debt before going public.